secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001739104-26-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco reports Q4 revenue up 12% to $1.14B, net loss $276M; provides 2026 guidance in line with outlook
--------------------------------------------------------------------------------

- Q4 2025 revenue $1,144M (+12% reported, +9% organic CC); reported net loss $276M, adjusted EPS $0.13.
- FY 2025 revenue $4,715M (+6% reported, +7% organic CC); reported net loss $232M, adjusted EPS $0.94.
- 2026 guidance: revenue $4,950-5,020M (4-6% organic CC growth), adjusted EBITDA $955-985M, adjusted EPS $1.00-1.06.
- Raising 2026 innovation revenue target to $1.15B; delivered all 'Big 6' blockbuster products by end of 2025 with Befrena approval in Q4.
- Recorded $155M restructuring charges in Q4 under Elanco Ascend; net leverage ratio improved to 3.6x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/0001739104-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/elan-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001739104-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer